Research
Hormonal
GLP-1 and GIP receptor agonists (semaglutide, tirzepatide) are teratogenic in animal models and lack human pregnancy safety data, necessitating discontinuation prior to conception.
Stop semaglutide or tirzepatide 1-2 months before you start trying to get pregnant. While no defects have been reported in humans yet, animal studies show potential risks, so it is safer to be off the medication before conception.
GoodSupportsHIGH confidence
Animal studies suggesting teratogenicity, as well as lack of pregnancy safety data, led to the recommendation to discontinue these medications 1-2 months prior to conception.
Why this rating
Strong animal data and manufacturer warnings; human data is limited but reassuring so far.
Source
Consideration of Use of Semaglutide and Tirzepatide Prior to Pregnancy
Alyse S. Goldberg · Canadian Women s Health Today · 2024
DOI 10.58931/cwht.2024.1210
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →